New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
08:02 EDTSNYSanofi Pasteur announces favorable Phase II results for Clostridium vaccine
Sanofi Pasteur, the vaccines division of Sanofi, presented Phase II trial results for an investigational vaccine for the prevention of Clostridium difficile infection. The Phase II trial met its primary objectives, reactions were generally mild and of short duration, and the candidate vaccine generated an immune response against C. diff toxins A and B. These toxins are largely responsible for CDI, which can cause potentially life-threatening gut inflammation and diarrhea. The Phase II vaccine study was a randomized, multi-center trial split into two stages. The first, conducted with 455 volunteers, was placebo-controlled, double-blind and designed for dose and formulation selection. The second, which included 206 additional volunteers, was designed to compare the dose and formulation chosen in the first stage against two alternate dosing schedules.
News For SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
05:23 EDTSNYSanofi, Regeneron announce Praluent ODYSSEY OUTCOMES trial enrollment complete
Subscribe for More Information
November 20, 2015
06:09 EDTSNYSanofi, AstraZeneca to exchange more than 210,000 compounds
Subscribe for More Information
November 18, 2015
08:11 EDTSNYIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use